

IMPACT FACTOR 4.3





an Open Access Journal by MDPI

Combatting Dental Infections: Insights into Oral Microbiota and Antibiotic Therapy

Guest Editors:

Prof. Dr. Biao Ren

State Key Laboratory of Oral Diseases, National Clinical Research Center for Oral Diseases, West China School of Stomatology, Sichuan University, Chengdu 610064, China

Dr. Jaya Seneviratne

School of Dentistry, University of Queensland, Herston, QLD, Australia

Deadline for manuscript submissions:

31 December 2024

Message from the Guest Editors

Oral microbiota is proved to be the first microbial strategic pass for the gastrointestinal tract. It is important for the maintenance of both oral and systematic health. The imbalance or instability of oral microbiota, including the overabundance of certain bacteria, viruses, or fungi, results in the development of dental infectious diseases. Increasing the understanding of the functions and mechanisms of oral microbiota is the essential way to develop new targets, therapeutic strategies, and control concepts for dental infections, even some systematic diseases. In this Special Issue, we will decipher the deep relationship and mechanisms between oral microbiota and dental or systematic diseases and construct novel control and regulation strategies for oral microbiota, including antibiotics. antimicrobial chemical molecules. antimicrobial biomaterials. biomacromolecules, probiotics, therapeutic technologies, etc., to combat oral microbiota-related dental or systematic diseases. The goal of this Special Issue is to provide the clinical relevance of new targets and therapeutic strategies based on oral microbiota for dental and systematic diseases.













an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. Antibiotics is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

Contact Us